©2022 Stanford Medicine
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Not Recruiting
Trial ID: NCT03163667
Purpose
The primary objective of this study is to compare the progression-free survival (PFS) of
participants treated with telaglenastat and everolimus versus placebo and everolimus for
advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the
following:
- At least 2 lines of therapy, including at least 1 vascular endothelial growth factor
tyrosine kinase inhibitor (VEGF TKI)
- Radiographic progression of metastatic RCC must have occurred (per investigator
assessment) on or after the most recent systemic therapy and within 6 months prior to
cycle 1 day 1
Official Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- Karnofsky Performance Score (KPS) ≥ 70%
- Estimated Life Expectancy of at least 3 months
- Documented histological or cytological diagnosis of renal cell carcinoma with a
clear-cell component.
- Measurable Disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as
determined by the Investigator
- Must have received at least two prior lines of systemic therapy, including at least
one VEGF TKI (e.g., sunitinib, sorafenib, pazopanib, cabozantinib)
a) Radiographic progression of mRCC must have occurred (per investigator assessment)
on or after the most recent systemic therapy and within 6 months prior to Cycle 1 Day
1 (C1D1).
- Prior treatment with other anti-cancer therapies including cytokines, monoclonal
antibodies, immunotherapies, and cytotoxic chemotherapy is allowed
Exclusion Criteria:
- Prior treatment with mammalian target of rapamycin (mTOR) inhibitors (everolimus or
temsirolimus) or CB-839
- Receipt of any anticancer therapy within the following windows before randomization:
- TKI therapy within 2 weeks or 5 half-lives, whichever is longer
- Any type of anti-cancer antibody within 4 weeks
- Cytotoxic chemotherapy within 4 weeks
- Investigational therapy within 4 weeks or 5 half-lives, whichever is longer
- Radiation therapy for bone metastasis within 2 weeks, any other external
radiation therapy within 4 weeks before randomization. Patients with clinically
relevant ongoing complications from prior radiation therapy are not eligible.
- Unable to receive medications orally (PO) or any condition that may prevent adequate
absorption of oral study medication
- Major surgery within 28 days prior to randomization
- Patients with active and/or untreated central nervous system (CNS) cancer are not
eligible. Patients with treated brain metastasis must have 1) documented radiographic
stability of at least 4 weeks duration demonstrated on baseline contrast-enhanced CNS
imaging (eg contrast-enhanced magnetic resonance imaging [MRI] of the brain) prior to
randomization and 2) must be symptomatically stable and off steroids for at least 2
weeks before randomization.
- Requirement for continued proton pump inhibitor after randomization
- Chronic treatment with corticosteroids or other immunosuppressive agents except (i)
inhaled or topical steroids or replacement dose corticosteroids equivalent to ≤ 10 mg
prednisone and (ii) patients receiving physiological doses of hydrocortisone for
adrenal insufficiency
Intervention(s):
drug: Placebo
drug: CB-839
drug: everolimus
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061